Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2015

Published: Oct, 2015 | Pages: 290 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2015', provides an overview of the Metastatic Renal Cell Carcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Metastatic Renal Cell Carcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Metastatic Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Renal Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Carcinoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents
2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Metastatic Renal Cell Carcinoma Overview 8
Therapeutics Development 9
Pipeline Products for Metastatic Renal Cell Carcinoma - Overview 9
Pipeline Products for Metastatic Renal Cell Carcinoma - Comparative Analysis 10
Metastatic Renal Cell Carcinoma - Therapeutics under Development by Companies 11
Metastatic Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 13
Metastatic Renal Cell Carcinoma - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Metastatic Renal Cell Carcinoma - Products under Development by Companies 18
Metastatic Renal Cell Carcinoma - Products under Investigation by Universities/Institutes 21
Metastatic Renal Cell Carcinoma - Companies Involved in Therapeutics Development 22
Acceleron Pharma, Inc. 22
Amgen Inc. 23
Angiogene Pharmaceuticals Limited 24
Argos Therapeutics, Inc. 25
Astellas Pharma Inc. 26
Bayer AG 27
Beta Pharma, Inc. 28
Bionomics Limited 29
Cellceutix Corporation 30
Celldex Therapeutics, Inc. 31
Cerulean Pharma, Inc. 32
Dr. Reddy's Laboratories Limited 33
EirGenix Inc. 34
Eisai Co., Ltd. 35
Eli Lilly and Company 36
Epirus Biopharmaceuticals, Inc. 37
Exelixis, Inc. 38
Genor BioPharma Co., Ltd. 39
GlaxoSmithKline Plc 40
Hetero Drugs Limited 41
Hospira, Inc. 42
immatics biotechnologies GmbH 43
Immune Design Corp. 44
Immunicum AB 45
Inbiopro Solutions Pvt. Ltd. 46
Mabion SA 47
Merck & Co., Inc. 48
NewLink Genetics Corporation 49
Novartis AG 50
Oncobiologics, Inc. 51
Ono Pharmaceutical Co., Ltd. 52
Panacea Biotec Limited 53
Peloton Therapeutics, Inc. 54
Prima BioMed Ltd. 55
Rexahn Pharmaceuticals, Inc. 56
Seattle Genetics, Inc. 57
Syndax Pharmaceuticals, Inc. 58
TVAX Biomedical, Inc. 59
Metastatic Renal Cell Carcinoma - Therapeutics Assessment 60
Assessment by Monotherapy Products 60
Assessment by Combination Products 61
Assessment by Target 62
Assessment by Mechanism of Action 66
Assessment by Route of Administration 69
Assessment by Molecule Type 71
Drug Profiles 73
AGS-16C3F - Drug Profile 73
aldesleukin - Drug Profile 74
bevacizumab biosimilar - Drug Profile 75
bevacizumab biosimilar - Drug Profile 76
bevacizumab biosimilar - Drug Profile 77
bevacizumab biosimilar - Drug Profile 78
bevacizumab biosimilar - Drug Profile 79
bevacizumab biosimilar - Drug Profile 80
bevacizumab biosimilar - Drug Profile 81
bevacizumab biosimilar - Drug Profile 82
bevacizumab biosimilar - Drug Profile 83
bevacizumab biosimilar - Drug Profile 84
bevacizumab biosimilar - Drug Profile 85
BNC-105 - Drug Profile 86
BPI-3119 - Drug Profile 88
cabozantinib s-malate - Drug Profile 89
capmatinib - Drug Profile 93
Cell Therapy for Metastatic Renal Cell Carcinoma - Drug Profile 96
CRLX-101 - Drug Profile 97
dalantercept - Drug Profile 100
Dendritic Cell Therapy for Metastatic Renal Cell Carcinoma and Melanoma - Drug Profile 102
entinostat - Drug Profile 103
everolimus - Drug Profile 107
G-305 - Drug Profile 113
IBPM-002BZ - Drug Profile 115
IMA-901 - Drug Profile 116
IMP-321 - Drug Profile 118
Intuvax - Drug Profile 120
KM-3174 - Drug Profile 124
lenvatinib - Drug Profile 128
LY-2510924 - Drug Profile 133
Monoclonal Antibody Conjugated to Target Cells Expressing Antigen G250 for Renal Cell Carcinoma - Drug Profile 135
nivolumab - Drug Profile 136
Orellanine - Drug Profile 143
panobinostat - Drug Profile 144
pazopanib hydrochloride + pembrolizumab - Drug Profile 150
pembrolizumab - Drug Profile 151
PT-2385 - Drug Profile 160
radium Ra 223 dichloride - Drug Profile 161
Recombinant Protein for Oncology - Drug Profile 164
rilotumumab - Drug Profile 165
rocapuldencel-t - Drug Profile 167
RX-0201 - Drug Profile 170
SGN-CD70A - Drug Profile 172
trebananib - Drug Profile 173
TVI-Kidney-1 - Drug Profile 176
varlilumab - Drug Profile 177
ZD-6126 - Drug Profile 179
Metastatic Renal Cell Carcinoma - Recent Pipeline Updates 180
Metastatic Renal Cell Carcinoma - Dormant Projects 273
Metastatic Renal Cell Carcinoma - Discontinued Products 276
Metastatic Renal Cell Carcinoma - Product Development Milestones 277
Featured News & Press Releases 277
Appendix 285
Methodology 285
Coverage 285
Secondary Research 285
Primary Research 285
Expert Panel Validation 285
Contact Us 285
Disclaimer 286

List of Tables

Number of Products under Development for Metastatic Renal Cell Carcinoma, H2 2015 13
Number of Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H2 2015 14
Number of Products under Development by Companies, H2 2015 15
Number of Products under Investigation by Universities/Institutes, H2 2015 17
Comparative Analysis by Late Stage Development, H2 2015 18
Comparative Analysis by Clinical Stage Development, H2 2015 19
Comparative Analysis by Early Stage Development, H2 2015 20
Comparative Analysis by Unknown Stage Development, H2 2015 21
Products under Development by Companies, H2 2015 22
Products under Development by Companies, H2 2015 (Contd..1) 23
Products under Development by Companies, H2 2015 (Contd..2) 24
Products under Investigation by Universities/Institutes, H2 2015 25
Metastatic Renal Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2015 26
Metastatic Renal Cell Carcinoma - Pipeline by Amgen Inc., H2 2015 27
Metastatic Renal Cell Carcinoma - Pipeline by Angiogene Pharmaceuticals Limited, H2 2015 28
Metastatic Renal Cell Carcinoma - Pipeline by Argos Therapeutics, Inc., H2 2015 29
Metastatic Renal Cell Carcinoma - Pipeline by Astellas Pharma Inc., H2 2015 30
Metastatic Renal Cell Carcinoma - Pipeline by Bayer AG, H2 2015 31
Metastatic Renal Cell Carcinoma - Pipeline by Beta Pharma, Inc., H2 2015 32
Metastatic Renal Cell Carcinoma - Pipeline by Bionomics Limited, H2 2015 33
Metastatic Renal Cell Carcinoma - Pipeline by Cellceutix Corporation, H2 2015 34
Metastatic Renal Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H2 2015 35
Metastatic Renal Cell Carcinoma - Pipeline by Cerulean Pharma, Inc., H2 2015 36
Metastatic Renal Cell Carcinoma - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015 37
Metastatic Renal Cell Carcinoma - Pipeline by EirGenix Inc., H2 2015 38
Metastatic Renal Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2015 39
Metastatic Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2015 40
Metastatic Renal Cell Carcinoma - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 41
Metastatic Renal Cell Carcinoma - Pipeline by Exelixis, Inc., H2 2015 42
Metastatic Renal Cell Carcinoma - Pipeline by Genor BioPharma Co., Ltd., H2 2015 43
Metastatic Renal Cell Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2015 44
Metastatic Renal Cell Carcinoma - Pipeline by Hetero Drugs Limited, H2 2015 45
Metastatic Renal Cell Carcinoma - Pipeline by Hospira, Inc., H2 2015 46
Metastatic Renal Cell Carcinoma - Pipeline by immatics biotechnologies GmbH, H2 2015 47
Metastatic Renal Cell Carcinoma - Pipeline by Immune Design Corp., H2 2015 48
Metastatic Renal Cell Carcinoma - Pipeline by Immunicum AB, H2 2015 49
Metastatic Renal Cell Carcinoma - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015 50
Metastatic Renal Cell Carcinoma - Pipeline by Mabion SA, H2 2015 51
Metastatic Renal Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2015 52
Metastatic Renal Cell Carcinoma - Pipeline by NewLink Genetics Corporation, H2 2015 53
Metastatic Renal Cell Carcinoma - Pipeline by Novartis AG, H2 2015 54
Metastatic Renal Cell Carcinoma - Pipeline by Oncobiologics, Inc., H2 2015 55
Metastatic Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 56
Metastatic Renal Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2015 57
Metastatic Renal Cell Carcinoma - Pipeline by Peloton Therapeutics, Inc., H2 2015 58
Metastatic Renal Cell Carcinoma - Pipeline by Prima BioMed Ltd., H2 2015 59
Metastatic Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2015 60
Metastatic Renal Cell Carcinoma - Pipeline by Seattle Genetics, Inc., H2 2015 61
Metastatic Renal Cell Carcinoma - Pipeline by Syndax Pharmaceuticals, Inc., H2 2015 62
Metastatic Renal Cell Carcinoma - Pipeline by TVAX Biomedical, Inc., H2 2015 63
Assessment by Monotherapy Products, H2 2015 64
Assessment by Combination Products, H2 2015 65
Number of Products by Stage and Target, H2 2015 67
Number of Products by Stage and Mechanism of Action, H2 2015 71
Number of Products by Stage and Route of Administration, H2 2015 74
Number of Products by Stage and Molecule Type, H2 2015 76
Metastatic Renal Cell Carcinoma Therapeutics - Recent Pipeline Updates, H2 2015 184
Metastatic Renal Cell Carcinoma - Dormant Projects, H2 2015 277
Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..1), H2 2015 278
Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..3), H2 2015 279
Metastatic Renal Cell Carcinoma - Discontinued Products, H2 2015 280